argenx SE ARGNF Stock
argenx SE Price Chart
argenx SE ARGNF Financial and Trading Overview
| argenx SE stock price | 865 USD |
| Previous Close | 865 USD |
| Open | 803.19 USD |
| Bid | 853 USD x 100 |
| Ask | 929.5 USD x 100 |
| Day's Range | 803.19 - 803.19 USD |
| 52 Week Range | 547.6 - 960.58 USD |
| Volume | 1 USD |
| Avg. Volume | 12 USD |
| Market Cap | 54.12B USD |
| Beta (5Y Monthly) | -0.04 |
| PE Ratio (TTM) | 33.00267 |
| EPS (TTM) | 26.21 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ARGNF Valuation Measures
| Enterprise Value | 48.96B USD |
| Trailing P/E | 33.00267 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 1.33 |
| Price/Sales (ttm) | 10.180713 |
| Price/Book (mrq) | 6.4269266 |
| Enterprise Value/Revenue | 9.211 |
| Enterprise Value/EBITDA | 30.354 |
Trading Information
argenx SE Stock Price History
| Beta (5Y Monthly) | -0.04 |
| 52-Week Change | 57.96% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 960.58 USD |
| 52 Week Low | 547.6 USD |
| 50-Day Moving Average | 886.88 USD |
| 200-Day Moving Average | 835.4 USD |
ARGNF Share Statistics
| Avg. Volume (3 month) | 12 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 62.56M |
| Float | 62.41M |
| Short Ratio | N/A |
| % Held by Insiders | 0.017% |
| % Held by Institutions | 47.91% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 32.26% |
| Operating Margin (ttm) | 31.99% |
| Gross Margin | 59.06% |
| EBITDA Margin | 30.34% |
Management Effectiveness
| Return on Assets (ttm) | 11.63% |
| Return on Equity (ttm) | 23.63% |
Income Statement
| Revenue (ttm) | 5.32B USD |
| Revenue Per Share (ttm) | 85.91 USD |
| Quarterly Revenue Growth (yoy) | 59.29% |
| Gross Profit (ttm) | 3.14B USD |
| EBITDA | 1.61B USD |
| Net Income Avi to Common (ttm) | 1.72B USD |
| Diluted EPS (ttm) | 26.21 |
| Quarterly Earnings Growth (yoy) | 92.20% |
Balance Sheet
| Total Cash (mrq) | 5.18B USD |
| Total Cash Per Share (mrq) | 82.89 USD |
| Total Debt (mrq) | 47M USD |
| Total Debt/Equity (mrq) | 0.56 USD |
| Current Ratio (mrq) | 5.123 |
| Book Value Per Share (mrq) | 134.59 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 974.19M USD |
| Levered Free Cash Flow (ttm) | 761.77M USD |
Profile of argenx SE
| Country | United States |
| State | N/A |
| City | Amsterdam |
| Address | Laarderhoogtweg 25 |
| ZIP | 1101 EB |
| Phone | 31 10 703 8441 |
| Website | https://argenx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1863 |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Q&A For argenx SE Stock
What is a current ARGNF stock price?
argenx SE ARGNF stock price today per share is 865 USD.
How to purchase argenx SE stock?
You can buy ARGNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for argenx SE?
The stock symbol or ticker of argenx SE is ARGNF.
Which industry does the argenx SE company belong to?
The argenx SE industry is Biotechnology.
How many shares does argenx SE have in circulation?
The max supply of argenx SE shares is 62.56M.
What is argenx SE Price to Earnings Ratio (PE Ratio)?
argenx SE PE Ratio is 33.00267000 now.
What was argenx SE earnings per share over the trailing 12 months (TTM)?
argenx SE EPS is 26.21 USD over the trailing 12 months.
Which sector does the argenx SE company belong to?
The argenx SE sector is Healthcare.
